

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/31 A61P5/08

A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) A61K C07K IPC 7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)


EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
Υ	B. BUYSE ET AL.: "Relief of slafter treatment of acromegaly: three cases and review of the l EUROPEAN RESPIRATORY JOURNAL, vol. 10, no. 6, 1997, pages 140 XP008029507 page 1404, left-hand column, la paragraph	report of iterature." 1–1404,	1-10
Y	J. DANGUIR: "The somatostatin SMS 201-995 promotes paradoxica aged rats." NEUROBIOLOGY OF AGING, vol. 10, no. 4, 1989, pages 367 XP001189333 page 369, right-hand column, la paragraph	1 sleep in -370,	1–10
X Furth	er documents are listed in the continuation of box C.	χ Patent family members are listed i	n annex.
"A" docume conside "E" earlier difiling de "L" docume which i citation "O" docume other n "P" docume later th	nt which may throw doubts on priority claim(s) or s cited to establish the publication date of another or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or	"T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an involve an involve and the document is combined with one or moments, such combination being obvior in the art. "&" document member of the same patent	the application but sory underlying the laimed invention be considered to current is taken alone laimed invention ventive step when the see other such docusto a person skilled family
-	April 2004	Date of mailing of the international seal	rch report
Name and m	alling address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Ryckebosch, A	

Interioral Colication No PCT/EP 14971

		PCT/EP 14971
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	J.C. REUBI ET AL.: "A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors." EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 456, 2002, pages 45-49, XP002276363 page 48, right-hand column, paragraph 2 -page 49, left-hand column, paragraph 1; figure 1B	1-10
X	WO 97/01579 A (SANDOZ AG ;ALBERT RAINER (CH); LEWIS IAN (CH); BAUER WILFRIED (CH)) 16 January 1997 (1997-01-16) cited in the application	9
Y	claims 1-5,8-10	1–10
X	WO 02/10192 A (NOVARTIS ERFIND VERWALT GMBH; ALBERT RAINER (CH); LEWIS IAN (CH);) 7 February 2002 (2002-02-07)	9,10
Υ	cited in the application page 1, paragraphs 1,2; claims 1-4,7,8,10	1-10
P,Y	WO 03/037256 A (YOUNG CHARLES W) 8 May 2003 (2003-05-08) page 10, last paragraph -page 14, last paragraph page 25, paragraph 4; claims 67-108; examples 7-20	1-10
	•	
į		
		<u>.</u> 1
		1





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X	Although claims 5-8 and partly claim 10 (as far as being dependent on claims 5-8) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Claims Nos.: 1-9 (all in part)
	because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-9 (all in part)

Present claims 1-9 (all in part) relate to the use of an extremely large number of possible somatostatin analogues. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the use of compound KE108 as specified on page 2, paragraph 2 of the description and mentioned in claim 1, and the compound as referred to in the description as "Compound A" (page 5, paragraph 1; page 8, item B) and claimed in claim 10.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Internal included in No
PCT/EP //14971

						149/1
	Patent document ed in search report		Publication date		Patent family member(s)	Publication date
WO	9701579	A	16-01-1997	AT	210152 T	15-12-2001
		••	10 01 100,	AU	714447 B2	06-01-2000
				AU	6515096 A	30-01-2000
				BR	9609335 A	
				CA	2222524 A1	25-05-1999
				CZ	9704196 A3	16-01-1997
				DE		13-05-1998
				DE	69617687 D1 69617687 T2	17-01-2002
				DK		22-08-2002
					835263 T3	02-04-2002
				MO	9701579 A2	16-01-1997
				EP	0835263 A2	15-04-1998
			•	ES	2169251 T3	01-07-2002
				HU	9901455 A2	28-09-1999
			•	JP	3445796 B2	08-09-2003
			•	JP	11506108 T	02-06-1999
				JP	2003104998 A	09-04-2003
				NO	976064 A	16-02-1998
				NZ	313147 A	29-11-1999
				PL	323943 A1	27-04-1998
				PT	835263 T	29-04-2002
				RU	2160741 C2	20-12-2000
				SI	835263 T1	30-06-2002
				SK	177097 A3	05-08-1998
				TR	9701718 T1	21-05-1998
				TW	491854 B	21-06-2002
-				US	6225284 B1	01-05-2001
				_ZA 	9605538 A	29-12-1997
WO	0210192	Α	07-02-2002	AU	8977801 A	13-02-2002
				BR	0112859 A	01-07-2003
				CA	2416293 A1	07-02-2002
				CN	1446229 T	01-10-2003
				CZ	20030288 A3	14-05-2003
				MO	0210192 A2	07-02-2002
				EP	1307486 A2	07-05-2003
				HU	0300684 A2	29-09-2003
				JP	2004505095 T	19-02-2004
				NO	20030484 A	19-03-2003
				SK 	1212003 A3	05-08-2003
WO	03037256	Α	08-05-2003	US	2003083241 A1	01-05-2003
				WO	03037256 A2	08-05-2003